Catalog No.
Product Name
Application
Product Information
Citations
-
Aniti-parasite Agent
epi-Ivermectin B1a is a significant derivative of Ivermectin, functioning as an anti-parasitic agent. This compound serves as a valuable tool for researching internal and external parasites, particularly in cattle. Its role in understanding the efficacy and safety of ivermectin-based formulations enhances its relevance in parasitology studies. -
Parasite Inhibitor
CWHM-1552 is a potent inhibitor of Plasmodium falciparum, demonstrating IC50 values of 51 nM and 53 nM against the 3D7 and Dd2 strains, respectively. This compound exhibits significant efficacy in oral administration and is designed for research applications focused on malaria treatment and parasite biology. CWHM-1552 serves as a valuable tool for studying antimalarial mechanisms and developing novel therapeutic strategies. -
Antileishmanial Agent
Trypaflavin is an acridine derivative recognized for its antileishmanial activity. It exerts its effects by targeting germ cells and inducing chromosomal aberrations in unfertilized oocytes, resulting in increased rates of genetic instability. Notably, Trypaflavin demonstrates significant toxicity toward Leishmania, leading to immediate lysis of leptomonads. This compound serves as a valuable tool in the study of leishmaniasis and related cellular processes. -
Parasite Inhibitor
Anticancer agent 140 is a compound designed as a parasite inhibitor, exhibiting significant potential for anticancer and antiparasitic activities. This reagent targets specific cellular pathways, making it valuable for research in cancer biology and parasitology. Its effectiveness in inhibiting parasite proliferation underscores its relevance in drug discovery and development for related diseases. -
SDH Inhibitor
Succinate dehydrogenase-IN-2 is a potent inhibitor targeting succinate dehydrogenase (SDH) with an IC50 value of 1.22 mg/L. This compound demonstrates significant antifungal activity, effectively inhibiting a range of fungal pathogens including S. sclerotiorum, V. mali, G. graminis, R. solani, and B. cinerea, with EC50 values in the range of 0.52-3.42 mg/L. It is a valuable tool for research applications focusing on fungal infections and metabolic pathways involving SDH. -
Parasite Inhibitor
Mirincamycin hydrochloride is a potent inhibitor of malaria, specifically targeting the early liver stages of Plasmodium. This compound demonstrates protective effects, effectively preventing the progression of the parasite during its initial infection phase. However, it is important to note that Mirincamycin does not eliminate dormant liver stages, as observed in studies utilizing a rhesus monkey model. This characteristic limits its applicability in certain therapeutic scenarios against malaria. -
Parasite Inhibitor
Allylpyrocatechol is a parasite inhibitor known for its antimalarial activity. This compound has been validated for its efficacy both in vitro and in vivo, demonstrating significant potential in combating malaria. Additionally, structure-activity relationship analyses of its analogs have been conducted, providing insights into the mechanisms underlying its biological effects. Its application in research can contribute to the development of novel antimalarial therapies. -
Parasite Inhibitor
BiPNQ is a potent inhibitor of Trypanosoma cruzi, the protozoan responsible for Chagas disease. This compound effectively disrupts the biological processes of the parasite, making it a valuable tool for research focused on the treatment of Chagas disease and the development of antiparasitic therapies. Its inhibitory activity may help elucidate the mechanisms of infection and potential therapeutic targets. -
Antileishmanial Agent
Antileishmanial agent-18 is an effective inhibitor of Leishmania donovani promastigote growth, targeting the parasite responsible for visceral leishmaniasis. This compound demonstrates notable antileishmanial activity while exhibiting a low cytotoxicity profile in host cells, making it a valuable tool for research into leishmaniasis treatment options. Its application is relevant in studies aimed at understanding parasite biology and developing new therapeutic strategies against leishmaniasis. -
Parasite Inhibitor
Ludaconitine, derived from Aconitum spicatum (Bruhl) Stapf, functions as a potent inhibitor of parasites. It demonstrates significant antileishmanial activity, exhibiting an IC50 of 36.10 μg/mL. This compound is valuable for research applications focused on leishmaniasis and the exploration of novel antiparasitic agents. -
Anti-parasite Agent
PAM 1392 is an anti-parasitic agent with demonstrated efficacy against Plasmodium berghei in murine models, as well as P. cynomolgi and P. knowlesi in non-human primates. Additionally, it exhibits significant anti-Trypanosoma cruzi activity in murine tissue cultures and acts against hemolytic streptococci in vitro. The dual antimalarial and antitrypanosomal properties of PAM 1392 make it a valuable compound for research focused on drug-resistant malaria and related parasitic diseases. -
Antileishmanial Agent
Antileishmanial agent-5 is a ribonucleoside analogue that exhibits potent activity against Leishmania infantum and Trypanosoma cruzi. It demonstrates effective antileishmanial properties, with EC50 values of 0.68 μM and 0.83 μM, respectively. This compound serves as a valuable tool for research applications focused on the treatment of leishmaniasis and Chagas disease. -
Parasite Inhibitor
Ep vinyl quinidine, an epi-vinyl stereoisomer of Quinidine, serves as a targeted inhibitor of parasitic activity. This compound exhibits significant potential in malaria research, leveraging its capabilities as a selective cytochrome P450db inhibitor. Additionally, it functions as a potassium channel blocker with an IC50 of 19.9 μM, positioning it as a valuable tool for investigating anti-parasitic mechanisms and therapeutic interventions. -
Antileishmanial Agent
DNDI-VL-2098 is an orally active antileishmanial agent targeting Leishmania parasites. It demonstrates high permeability and in vitro metabolic stability while selectively inhibiting CYP2C19, with an IC50 of 0.47 μM, without affecting other major CYP enzymes at concentrations up to 12.5 μM. This compound exhibits favorable pharmacokinetic properties across various animal models, including mice, hamsters, rats, and dogs, with moderate to high plasma protein binding. DNDI-VL-2098 is a valuable reagent for the study of visceral leishmaniasis. -
Parasite Inhibitor
Antileishmanial agent-1 specifically targets Leishmania parasites, demonstrating potent inhibitory activity against L. amazonensis promastigotes with an IC50 of 15.52 μM and intracellular amastigotes with an IC50 of 4.10 μM. This compound is valuable for research focused on leishmaniasis treatment, facilitating studies on parasite bioenergetics and drug resistance mechanisms. Its ability to effectively inhibit parasite growth makes it a significant tool in the development of antileishmanial therapies. -
Antileishmanial Agent
Antileishmanial agent-15 primarily targets Leishmania spp. and exhibits significant antileishmanial activity. This compound demonstrates cytotoxic effects against L. major promastigotes and amastigotes, with IC50 values of 0.78 μM and 0.99 μM, respectively. It serves as a valuable tool for research aimed at developing treatments for leishmaniasis. -
HCV Protease Inhibitor
MK-2748 is a potent inhibitor of the hepatitis C virus (HCV) NS3/4A protease. It demonstrates broad-spectrum antiviral activity across all genotypes (gt1a-gt6) with nanomolar potency (IC₅₀ < 0.115 nM), including strong efficacy against drug-resistant mutant strains such as gt1b R155K (IC₅₀ = 0.032 nM) and D168Y (IC₅₀ = 0.057 nM). MK-2748 is valuable for research on HCV infection and contributes to the understanding of antiviral mechanisms and treatment strategies. -
HCV Protease Inhibitor
AL-611 is an inhibitor of the Hepatitis C virus (HCV) NS5B polymerase, demonstrating potent activity with an EC50 value of 5 nM. This compound plays a critical role in antiviral research, particularly in the development of therapeutic strategies against HCV infections. Its effectiveness in inhibiting HCV replication makes it a valuable tool for studies focused on viral RNA synthesis and enzyme interactions. -
HCV Protease Inhibitor
GSK2818713 is a selective Hepatitis C virus (HCV) protease inhibitor that disrupts the replication complex associated with the NS5A protein. This compound exhibits potent anti-HCV activity, making it a valuable tool for studying the replication and life cycle of the virus. GSK2818713 is applicable in research focused on developing therapeutic strategies against Hepatitis C. -
HCV Protease Inhibitor
BI-1230 is a potent inhibitor of the HCV NS3 protease, exhibiting nanomolar activity in blocking viral replication. It demonstrates high selectivity against other serine and cysteine proteases, making it a valuable tool for studying hepatitis C virus infection mechanisms. Additionally, BI-1230 shows favorable pharmacokinetic properties, supporting its potential use in drug development and research applications related to antiviral therapy. -
HCV Protease Inhibitor
MK-6169 is a potent hepatitis C virus (HCV) protease inhibitor that targets the viral NS5A protein. It exhibits broad-spectrum activity against various HCV genotypes, making it a valuable tool for research on antiviral therapies in hepatitis C. This compound is useful for exploring the mechanisms of HCV replication and potential treatment strategies in pharmaceutical development. -
HCV Protease Inhibitor
Isoeuphorbetin is a dimeric coumarin that acts as a potent inhibitor of HCV protease, demonstrated by an IC50 value of 3.63 µg/mL. This compound has significant potential in antiviral research, particularly in the development of therapeutics targeting hepatitis C virus infection. Its ability to effectively block viral protease activity makes it a valuable tool for studying HCV biology and drug discovery. -
HCV Protease Inhibitor
Ac-D-DGla-LI-Cha-C is a potent inhibitor of the hepatitis C virus (HCV) protease, effectively disrupting viral replication. This peptide is instrumental in studying various biological processes and diseases, including cancer, autoimmune disorders, fibrotic conditions, inflammatory responses, neurodegenerative diseases, infectious diseases, lung and cardiovascular disorders, as well as metabolic diseases. Its targeted action on HCV protease makes it a valuable tool for research in virology and therapeutic development. -
HIV-1 Capsid Inhibitor
Lenacapavir is an HIV-1 capsid inhibitor that targets the interface between capsid hexamers and CA monomers, disrupting capsid assembly and viral maturation. This compound inhibits the nuclear translocation of HIV-1 DNA and interferes with CA-mediated protein-protein interactions, resulting in reduced formation of 2-LTR circles and pre-integration proviruses. Additionally, Lenacapavir induces aberrant capsids and decreases the production of mature HIV-1. It demonstrates efficacy against various HIV-1 subtypes and clinical isolates, making it a valuable reagent for research on HIV-1 infection. -
HIV-1 RT Inhibitor
Tenofovir diphosphate disodium is a potent inhibitor of HIV-1 reverse transcriptase, with a Ki value of 1.55 μM for DNA and 0.022 μM for RNA. This compound exhibits key biological activity as an antiretroviral agent, making it a valuable tool for the study of HIV and AIDS. It is suitable for research applications focused on understanding viral replication and developing therapeutic strategies against HIV infection. -
CCR7 and CXCR2 Antagonist
Cosalane is a dual antagonist of the chemokine receptors CCR7 (IC50 = 2.43 μM) and CXCR2 (IC50 = 0.66 μM). This compound effectively inhibits HIV replication across a variety of strains, including HIV-1, HIV-2, Rauscher murine leukemia virus, as well as herpes simplex viruses HSV-1 and HSV-2, and human cytomegalovirus. Cosalane disrupts the interaction between gp120 and CD4, inhibiting signaling downstream of CCR7 in response to its ligands CCL19 and CCL21. Research applications include studies on HIV and the potential modulation of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. -
HIV-1 TAT Peptide
TAT (YGRKKRRQRRR) is a cell-penetrating peptide derived from the transactivator of transcription (TAT) of human immunodeficiency virus-1 (HIV-1). It enhances the solubility and yield of heterologous proteins, making it a valuable tool in research applications related to protein expression and purification. TAT's ability to facilitate cellular uptake has made it a useful reagent in studies exploring intracellular delivery mechanisms and molecular therapeutics. -
CCR5 Inhibitor
DAPTA is a synthetic peptide that acts as a selective inhibitor of the CCR5 receptor. By blocking CCR5, DAPTA interferes with viral entry into host cells, exhibiting significant anti-HIV activity. This compound is valuable for research in virology and the development of therapeutic strategies against HIV. -
HIV-1 Inhibitor
PYR01 is a non-nucleoside reverse transcriptase inhibitor that targets HIV-1 by activating the death of infected cells. It exhibits significant antiviral activity, demonstrating IC50 values of 27.5 nM and 39.7 nM for cytotoxic and antiviral effects, respectively. By promoting HIV-1 Gag-Pol dimerization and intracellular activation of HIV-1 protease, PYR01 induces selective cytotoxicity in HIV-1-infected cells. This compound is valuable for research focused on HIV biology and therapeutic strategies. -
HIV-1 Inhibitor
PF-3450074 is a specific inhibitor of the HIV-1 capsid protein (CA), exhibiting broad-spectrum antiviral activity against various HIV isolates with submicromolar potency (EC50=8-640 nM). This compound functions at an early stage of the HIV-1 life cycle, impeding viral replication by competing with the binding of nuclear host factors CPSF6 and NUP153. Additionally, PF-3450074 disrupts key processes such as uncoating, assembly, and reverse transcription, making it a valuable tool for HIV research. -
CD4-Targeted HIV Inhibitor
Cyclotriazadisulfonamide (CADA) is a selective inhibitor of HIV entry that targets CD4. It functions by inhibiting the co-translational translocation of human CD4 into the endoplasmic reticulum lumen in a signal peptide-dependent manner. In addition, CADA acts as a Sec61 translocon inhibitor, making it a valuable tool for studying HIV pathogenesis and potential therapeutic strategies against HIV infection. -
HIV-1 Inhibitor
Glycolithocholic acid 3-sulfate is a cholic acid derivative that serves as an effective HIV-1 inhibitor. It demonstrates the ability to inhibit the replication of HIV-1 in vitro, making it a valuable tool for studying HIV infection. Additionally, Glycolithocholic acid 3-sulfate may have relevance in research related to gallbladder disease. -
V-ATPase/HIV-1 Inhibitor
Diphyllin is a potent inhibitor of vacuolar H+-ATPase (V-ATPase) with an IC50 of 17 nM, and also acts as an HIV-1 inhibitor with an IC50 of 0.38 μM. This compound effectively disrupts the acidification of osteoclast lysosomes, leading to significant inhibition of osteoclast-mediated bone resorption while leaving osteoblastic bone formation unaffected. Diphyllin is valuable for investigating bone metabolism-related diseases and exploring therapeutic avenues for conditions characterized by excessive bone resorption. -
HIV Inhibitor
Censavudine is a nucleoside reverse transcriptase inhibitor that exhibits potent antiviral activity against HIV. With EC50 values ranging from 30 nM to 81 nM for HIV-2 and 450 nM to 890 nM for HIV-1, this compound is effective in disrupting viral replication. Additionally, Censavudine possesses a reactive alkyne group, allowing it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc), making it a versatile tool for click chemistry applications in drug development and molecular biology research. -
HIV gag mRNA Antagonist
Trecovirsen is an antiviral agent that targets HIV gag mRNA by hybridizing with its complementary sequence at the initiation site. This interaction leads to the induction of a reversible, dose-dependent prolongation of activated partial thromboplastin time due to its polyanionic properties. Trecovirsen is applicable for research on HIV infection, providing insights into the mechanisms of viral replication and potential therapeutic strategies. -
HIV/NRTTI Inhibitor
MK-8527 is an orally active inhibitor of HIV that functions as a nucleoside reverse transcriptase translocation inhibitor (NRTTI). This compound exhibits antiviral activity by impeding reverse transcriptase, an essential enzyme for viral replication. MK-8527 is primarily utilized in research focused on the development of HIV therapeutic strategies and studying mechanisms of resistance in retroviral infections. -
HIV Inhibitor
2',3'-Dideoxyadenosine is an inhibitor of HIV replication that functions by incorporating into viral DNA, thereby terminating chain elongation. This compound exhibits significant antiretroviral activity and is utilized in research to understand mechanisms of HIV infection and the development of therapeutic strategies against the virus. Its efficacy makes it a valuable tool in antiviral studies and drug development pipelines focused on HIV. -
HIV-1 Polypeptide
HIV-1 TAT (48-60) is a cell-penetrating peptide derived from residues 48-60 of the HIV-1 Tat protein, functioning as a facilitator for cellular uptake. This peptide enables the effective delivery of exogenous macromolecules into cells without causing disruption to cellular integrity. Its unique mechanism enhances research applications in drug delivery, gene therapy, and the study of intracellular processes associated with HIV-1. -
HIV Inhibitor
Zingibroside R1 is a dammarane-type triterpenoid saponin that targets HIV through its inhibitory effects. Isolated from the rhizomes, taproots, and lateral roots of Panax japonicus C. A. Meyer, it demonstrates anti-HIV-1 activity, in addition to notable anti-tumor and anti-angiogenic properties. Zingibroside R1 also inhibits 2-deoxy-D-glucose (2-DG) uptake in EAT cells with an IC50 of 91.3 μM, highlighting its potential for further research in cancer and viral therapies. -
HIV Inhibitor
(R)-Edelfosine, also known as (R)-ET-18-OCH3, is an ether lipid analog that primarily targets HIV through its antiviral properties. This compound exhibits significant anti-HIV activity and demonstrates potential antineoplastic effects. It is commonly utilized in research applications related to antiviral therapies and cancer treatment investigations. -
HIV-1 reverse transcriptase Inhibitor
Ulonivirine is an orally active non-nucleoside inhibitor of HIV-1 reverse transcriptase, targeting the hydrophobic binding pocket adjacent to the enzyme's polymerase active site. It effectively disrupts viral replication, making it a valuable tool for research focused on HIV-1 infection and the mechanisms of antiretroviral resistance. Ulonivirine is suitable for studies aimed at understanding HIV-1 pathogenesis and developing therapeutic interventions. -
HIV-1 Integrase Inhibitor
Bictegravir sodium is a highly potent inhibitor of HIV-1 integrase, demonstrating an IC50 of 7.5 nM. This compound exhibits robust and selective anti-HIV activity while maintaining low cytotoxicity. Bictegravir sodium is primarily utilized in research focused on HIV treatment strategies and the development of antiretroviral therapies. -
HIV-1 Integrase Inhibitor
1-Butyl-3-methylimidazolium bis(trifluoromethylsulfonyl)imide is a potent inhibitor of HIV-1 integrase, targeting both the 3'-processing and strand transfer stages of the integration process. This compound serves as a valuable tool in HIV-1 research, facilitating the study of viral replication and integration mechanisms. Its effectiveness in inhibiting key steps in the integration pathway makes it an important reagent for investigations related to HIV-1 therapeutic development. -
HIV-1 Inhibitor
BIT-225 is an HIV-1 inhibitor that specifically targets the Vpu protein by blocking its ion channel function. This mechanism effectively inhibits the release of HIV-1, particularly in monocyte-derived macrophages, with an EC50 of 2.25 μM. BIT-225 demonstrates a favorable safety profile, exhibiting minimal cytotoxicity (TC50 of 284 μM). This compound is valuable for research into therapeutic strategies for HIV-1. -
HIV Inhibitor
APOBEC3G-IN-1 is a potent inhibitor of the HIV virus that targets the APOBEC3G enzyme. This compound demonstrates significant activity in inhibiting viral replication, making it a valuable tool in HIV research. Its ability to modulate the immune response against HIV provides insights into viral pathogenesis and potential therapeutic strategies. -
HIV-1 Polypeptide
TAT (48-57) is a cell-permeable peptide derived from the HIV-1 transactivator of transcription (Tat) protein, specifically residues 48 to 57. This peptide facilitates the study of viral gene expression and replication by interacting with intracellular targets to enhance the transcriptional activity of HIV-1. TAT (48-57) is utilized in research applications focused on HIV pathogenesis, viral life cycle analysis, and the development of antiviral strategies. -
CCR5 Antagonist
Aplaviroc hydrochloride is a potent CCR5 antagonist targeting the CCR5 co-receptor. It demonstrates biological activity with IC50 values ranging from 0.1 to 0.4 nM against various HIV-1 strains, including HIV-1Ba-L, HIV-1JRFL, and HIV-1MOKW. This compound is valuable for research applications focused on HIV entry inhibition and the development of antiviral therapies. -
Anti-HIV Agent
Tucaresol is an orally bioavailable immunopotentiator that enhances T-helper cell activity, evidenced by increased levels of IL-2 and IFN-γ in both mice and humans. This compound exhibits anti-HIV properties, making it a valuable tool in the research of HIV infections and potential treatments. Its ability to modulate immune responses positions Tucaresol as a significant candidate for studies focused on immunological interventions in viral infections. -
Influenza Virus Inhibitor
Sodium copper chlorophyllin B is a sodium-copper complex of chlorophyll with demonstrated antiviral activity against the Influenza virus, exhibiting IC50 values between 50 to 100 μM. It also shows potential activity against HIV. This compound is primarily utilized in research applications aimed at understanding antiviral mechanisms and developing therapeutic strategies for viral infections. -
HIV-1 Nucleocapsid Protein Inhibitor
Claficapavir is a potent inhibitor of the HIV-1 nucleocapsid protein, specifically designed to interfere with its chaperone functions. With an IC50 of approximately 1 μM and a strong binding affinity (Kd = 20 nM), Claficapavir exhibits significant antiviral activity against HIV-1. This compound serves as a valuable tool for research focused on HIV pathogenesis and therapeutic interventions targeting viral replication.
